RPL5 and lung carcinoma: To illustrate which domain(s) or amino acid(s) of RBM10 would be a key for its suppression of c-Myc activation through uL18 and uL5, we employed the lung cancer–derived mutant RBM10-I316F (40) (Fig. 5A), which markedly increased lung adenocarcinoma (LUAD) A549 cell proliferation in cell culture (40).